119 related articles for article (PubMed ID: 35777027)
21. Immune infiltration-associated serum amyloid A1 predicts favorable prognosis for hepatocellular carcinoma.
Zhang W; Kong HF; Gao XD; Dong Z; Lu Y; Huang JG; Li H; Yang YP
World J Gastroenterol; 2020 Sep; 26(35):5287-5301. PubMed ID: 32994688
[TBL] [Abstract][Full Text] [Related]
22. Identification of cancer stem cell characteristics in liver hepatocellular carcinoma by WGCNA analysis of transcriptome stemness index.
Bai KH; He SY; Shu LL; Wang WD; Lin SY; Zhang QY; Li L; Cheng L; Dai YJ
Cancer Med; 2020 Jun; 9(12):4290-4298. PubMed ID: 32311840
[TBL] [Abstract][Full Text] [Related]
23. High MYBL2 expression and transcription regulatory activity is associated with poor overall survival in patients with hepatocellular carcinoma.
Guan Z; Cheng W; Huang D; Wei A
Curr Res Transl Med; 2018 Mar; 66(1):27-32. PubMed ID: 29274707
[TBL] [Abstract][Full Text] [Related]
24. Implications of m6A-associated snRNAs in the prognosis and immunotherapeutic responses of hepatocellular carcinoma.
Zhang C; Zhang W; Shui Y; Li P; Tian Z; Duan S; Wei Q
Front Immunol; 2022; 13():1001506. PubMed ID: 36405741
[TBL] [Abstract][Full Text] [Related]
25. A novel m6A-related prognostic signature for predicting the overall survival of hepatocellular carcinoma patients.
Xie S; Wang Y; Huang J; Li G
IET Syst Biol; 2022 Feb; 16(1):1-17. PubMed ID: 34647424
[TBL] [Abstract][Full Text] [Related]
26. ncRNA-Mediated High Expression of LPCAT1 Correlates with Poor Prognosis and Tumor Immune Infiltration of Liver Hepatocellular Carcinoma.
Sun Q; Liu X; Peng Q; Hu L; Jiang X
J Immunol Res; 2022; 2022():1584397. PubMed ID: 35615532
[TBL] [Abstract][Full Text] [Related]
27. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma.
Xie C; Wu H; Pan T; Zheng X; Yang X; Zhang G; Lian Y; Lin J; Peng L
Aging (Albany NY); 2021 Mar; 13(6):8563-8587. PubMed ID: 33714200
[TBL] [Abstract][Full Text] [Related]
28. Comprehensive analysis of N
Zhu HX; Lu WJ; Zhu WP; Yu S
J Clin Lab Anal; 2021 Dec; 35(12):e24071. PubMed ID: 34741346
[TBL] [Abstract][Full Text] [Related]
29. Comprehensive Analysis on the Specific Role and Function of Mitochondrial Inner Membrane Protein MPV17 in Liver Hepatocellular Carcinoma.
Tao H; Wang C; Lu C; Ma N; Zhu Y; Xuan S; Zhou X
Genet Res (Camb); 2022; 2022():7236823. PubMed ID: 35919033
[TBL] [Abstract][Full Text] [Related]
30. High Trophinin-Associated Protein Expression Is an Independent Predictor of Poor Survival in Liver Cancer.
Jiao Y; Li Y; Lu Z; Liu Y
Dig Dis Sci; 2019 Jan; 64(1):137-143. PubMed ID: 30284652
[TBL] [Abstract][Full Text] [Related]
31. Correlation analysis of RDM1 gene with immune infiltration and clinical prognosis of hepatocellular carcinoma.
Qiu C; Li Z; Cao W; Cai X; Ye L; Zhang C; Ma Y; Wang X; Yang Y
Biosci Rep; 2021 Sep; 41(9):. PubMed ID: 34435618
[TBL] [Abstract][Full Text] [Related]
32. SLC41A3 Exhibits as a Carcinoma Biomarker and Promoter in Liver Hepatocellular Carcinoma.
Chang Q; Xu Y; Wang J; Jing H; Rao L; Tang W; Zhang Z; Wu X
Comput Math Methods Med; 2021; 2021():8556888. PubMed ID: 34819993
[TBL] [Abstract][Full Text] [Related]
33. Development and validation of an ECM-related prognostic signature to predict the immune landscape of human hepatocellular carcinoma.
Wu G; Yang Y; Ye R; Yue H; Zhang H; Huang T; Liu M; Zheng Y; Wang Y; Zhou Y; Guo Q
BMC Cancer; 2022 Oct; 22(1):1036. PubMed ID: 36195857
[TBL] [Abstract][Full Text] [Related]
34. Classification of early and late stage liver hepatocellular carcinoma patients from their genomics and epigenomics profiles.
Kaur H; Bhalla S; Raghava GPS
PLoS One; 2019; 14(9):e0221476. PubMed ID: 31490960
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of Low-density lipoprotein receptor-related protein 1B (LRP1B) inhibits the progression of hepatocellular carcinoma cells by activating the endoplasmic reticulum stress signaling pathway.
Zhen Z; Shen Z; Sun P
Bioengineered; 2022 Apr; 13(4):9467-9481. PubMed ID: 35389768
[TBL] [Abstract][Full Text] [Related]
36. Development of an immune-related prognostic index associated with hepatocellular carcinoma.
Hu B; Yang XB; Sang XT
Aging (Albany NY); 2020 Mar; 12(6):5010-5030. PubMed ID: 32191631
[TBL] [Abstract][Full Text] [Related]
37. Pan-cancer analysis of the oncogenic role of HNRNPR in human tumors.
Yang Y; Sun JD; Xiang ZL
Cell Biol Int; 2023 Aug; 47(8):1406-1426. PubMed ID: 37077028
[TBL] [Abstract][Full Text] [Related]
38. Identification of a Necroptosis-Related Prognostic Signature and Associated Regulatory Axis in Liver Hepatocellular Carcinoma.
He A; Huang Z; Wang J; Lu H; Zhang R; Wu L; Feng Q
Dis Markers; 2022; 2022():3968303. PubMed ID: 35855852
[TBL] [Abstract][Full Text] [Related]
39. Development of a Predictive Immune-Related Gene Signature Associated With Hepatocellular Carcinoma Patient Prognosis.
Lei J; Zhang D; Yao C; Ding S; Lu Z
Cancer Control; 2020; 27(1):1073274820977114. PubMed ID: 33269615
[TBL] [Abstract][Full Text] [Related]
40. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]